Form 4: Inspire Medical Director Sells Shares Under 10b5-1 Plan

Inspire Medical Systems Director Shawn McCormick sold 1,200 shares of common stock for $139 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Shawn McCormick, a Director at Inspire Medical Systems, Inc. (INSP), sold 1,200 shares of common stock.
• The transaction occurred on December 2, 2025, at a price of $139 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan established on August 29, 2025.
• Following the transaction, McCormick directly owns 24,846 shares and indirectly owns 3,000 shares through a trust.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically minimizes negative sentiment associated with insider selling. However, any insider sale can be viewed with slight caution.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new, non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can be perceived as a slight negative signal by some investors, though the amount is relatively small compared to total holdings.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• "All sale transactions reported herein were made pursuant to a Rule 10b5-1 trading plan dated August 29, 2025."

Industry Context

This Form 4 filing details a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• Sale of 1,200 shares of common stock by Director Shawn McCormick to the open market at $139 per share.

Stakeholder Impact

• Shareholders may interpret the director's sale as a minor negative signal, though the 10b5-1 plan mitigates concerns about opportunistic selling. The volume of shares sold is not significant enough to cause major price disruption.

Key Dates

Recommendation

The filing details a routine insider sale under a 10b5-1 plan, which does not provide new fundamental information about the company's performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this transaction. Investors should hold their position and look for more substantive company updates.

Keywords

Inspire Medical Systems, INSP, Shawn McCormick, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction